Clinical trials: Adenosine
Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG
Phase II, randomized, double-masked study to evaluate the efficacy and tolerability of topical ocular delivery of fixed-dosed combinations of trabodenoson and latanoprost in subjects with Ocular Hypertension or Primary Open-Angle…
- Trial name
- NCT02829996
- Testing
- trabodenoson 6.0% / latanoprost 0.005% QD, trabodenoson 3.0% / latanoprost 0.005% QD, trabodenoson 6.0% / latanoprost 0.0025% QD
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Inotek Pharmaceuticals Corporation
Immunologic Deficiency Syndromes
Strimvelis Registry Study to Follow-up Patients With Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID)
Adenosine deaminase (ADA) enzyme deficiency results in severe combined immunodeficiency (SCID), a fatal autosomal recessive inherited immune disorder.
- Trial name
- NCT03478670
- Testing
- Strimvelis
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Fondazione Telethon
Adenosine Deaminase Deficiency
Gene Therapy ADA Deficiency
Adenosine deaminase deficiency is an inherited disorder that results in severe abnormalities of the immune system and leaves children unable to fight infection.
- Trial name
- NCT01279720
- Testing
- Intravenous infusion of transduced cells
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- Great Ormond Street Hospital for Children NHS Foundation Trust
Blood Flow Speed, Coronary Flow Velocity
Study to Assess the Effect of Ticagrelor on Coronary Blood Flow in Healthy Male Subjects.
The purpose of this study is to determine if Ticagrelor increases the Adenosin induced coronary blood flow velocity.
- Trial name
- NCT01226602
- Testing
- AZD6140
- Where
- Sweden
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Atrial Fibrillation
Kansai Plus Atrial Fibrillation Trial
This is a 2x2 factorial randomized controlled trial (KPAF Trial), evaluating two different pharmacological approaches to improve long-term outcome of catheter ablation for atrial fibrillation (AF).
- Trial name
- KPAF (NCT01477983)
- Testing
- ATP guide additional ablation., Antiarrhythmic drug (AAD), Control
- Where
- Japan
- Volunteers
- 2,113 people
- Sponsor
- Kyoto University, Graduate School of Medicine
Health
Phase I Dose-Escalation Study to Evaluate Tolerability, Safety & PK of INO-8875 in Healthy Older-Adult Volunteers
The purpose of this study is to evaluate how tolerable and safe it is to give INO-8875 eye drops at different concentrations to normal older healthy adult volunteers for two weeks.
- Trial name
- NCT01123772
- Testing
- INO-8875
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Inotek Pharmaceuticals Corporation
Solid Tumours
Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours
The purpose of this modular, first trial in human study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of ascending dose levels (DLs) of AZD4956 monotherapy and in…
- Trial name
- PARTHENON (NCT07446855)
- Testing
- AZD4956, Saruparib
- Where
- 19 sites in United States, Australia and 4 more
- Volunteers
- 180 people
- Sponsor
- AstraZeneca
Locally Advanced or Metastatic NSCLC
PBF-1129 in Patients With NSCLC
Phase I clinical trial in Eastern Cooperative Oncology Group (ECOG) 0-1 patients with locally advanced or metastatic NSCLC to evaluate safety and tolerability of the compound PBF-1129, an Adenosine A2b receptor antagonist.
- Trial name
- NCT03274479
- Testing
- PBF-1129
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Palobiofarma SL
Ovarian Neoplasms
A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
This study aims to assess efficacy of Niraparib (GSK3985771) as maintenance treatment in participants with Stage III or IV ovarian cancer.
- Trial name
- NCT02655016
- Testing
- Niraparib
- Where
- 116 sites in United States, Belgium and 12 more
- Volunteers
- 733 people
- Sponsor
- Tesaro, Inc.
HER2/Neu Positive, Recurrent Breast Carcinoma
Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery
This phase I trial studies the side effects and best way of giving trastuzumab emtansine in treating patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer that has spread to other parts of the body…
- Conditions
- HER2/Neu Positive, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Trial name
- NCT01816035
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Trastuzumab Emtansine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Washington
Atrial Fibrillation
Role and Interactions of Adenosine, Receptors, Methionine Cycle Nutritional, Metabolic and Genetic Determinants in the Onset of Atrial Fibrillation in Normal Heart
The purpose of this study is to analyze the association of atrial fibrillation onset in normal heart and: Genetic determinants (genes of receptors, enzymes involved in synthesis and degradation, genes of bioavailability of…
- Trial name
- FACS (NCT02885740)
- Testing
- Quantification assay of adenosine and methionine cycle metabolites, Polymorphism analysis of genes related to adenosine metabolism and methionine cycle, Quantitative and qualitative nutritional evaluation
- Where
- France
- Volunteers
- 400 people
- Sponsor
- Central Hospital, Nancy, France
Peripheral Artery Disease, Vascular Disease
Adenosine-induced Myocardial Blood Flow in Peripheral Artery Disease Patients
The purpose of the study is to assess the effect of blood flow to the heart when subjects are treated with ticagrelor (Brilinta) or clopidogrel (antiplatelet drugs that stop the blood from clumping together) in patients with…
- Conditions
- Peripheral Artery Disease, Vascular Disease, Arterial Occlusion Disease, Intermittent Claudication
- Trial name
- PAD (NCT02121288)
- Testing
- Ticagrelor, clopidogrel
- Sponsor
- AstraZeneca
Overactive Bladder
Urinary Nerve Growth Factor (NGF), Prostaglandin E2 (PGE2)and Adenosine Triphosphate (ATP): Potential Biomarkers in Overactive Bladder Patients
Nerve growth factor (NGF), prostaglandin E2 (PGE2)and adenosine triphosphate (ATP) levels in urine were reported to increase in patients with overactive bladder (OAB).
- Trial name
- NCT01499069
- Testing
- Oxybutinin, Fesoterodine, Solifenacin, Propiverin, Trospium
- Where
- South Korea
- Volunteers
- 191 people
- Sponsor
- Samsung Medical Center
Coronary Artery Disease
Efficacy and Safety Study of Binodenoson in Assessing Cardiac Ischemia
Binodenoson (an experimental drug) and adenosine (an FDA-approved drug that is currently used by doctors) are used to increase blood flow to the heart just like when a person exercises on a treadmill.
- Trial name
- VISION-302 (NCT00944294)
- Testing
- binodenoson, adenosine
- Volunteers
- 419 people
- Sponsor
- Pfizer
Methotrexate, Vasodilation
The Influence of Methotrexate on the Metabolism and Vascular Effects of Adenosine in Humans
In this study we aim to determine whether methotrexate influences the metabolism and vascular effects of adenosine in humans in vivo. Adenosine is an endogenous purine-nucleoside with potent anti-inflammatory effects.
- Trial name
- NCT00184886
- Testing
- Methotrexate 15 mg/week for 12 weeks
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Radboud University Medical Center
Coronary Artery Disease
Assessing Myocardial Blood Flow and Blood Flow Reserve by Transoesophageal Echocardiography (TEE)
Until today it was not possible to reliably assess the function of a new bypass, i.e., to measure myocardial perfusion. Measuring intramyocardial blood flow directly after revascularisation would greatly improve the assessment of…
- Trial name
- NCT00286559
- Testing
- SonoVue, Optison
- Sponsor
- University Hospital, Basel, Switzerland
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia
8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
This phase I/II trial studies the side effects and best dose of 8-chloroadenosine and to see how well it works in treating patients with acute myeloid leukemia that has returned after a period of improvement (relapsed) or does…
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT02509546
- Testing
- 8-Chloroadenosine, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Acute Respiratory Distress
The ARCTIC Trial: Aerosolized Inhaled Adenosine Treatment in Patients With Acute Respiratory Distress Syndrome (ARDS) Caused by COVID-19
This is a phase II study to test adenosine efficacy for down-regulation of the overwhelming inflammation of COVID-19 in the lungs as reflected by clinical recovery of lung function; resolution of clinically relevant markers of…
- Trial name
- NCT04588441
- Testing
- Adenosine
- Sponsor
- University of Florida
Neuropathic Pain
The Study of GW493838, an Adenosine A1 Agonist, in Peripheral Neuropathic Pain
The purpose of this study was to determine the analgesic effect of GW493838 in patients with post-herpetic neuralgia or peripheral nerve injury caused by trauma or surgery.
- Trial name
- NCT00376454
- Testing
- GW493838
- Where
- 32 sites in United States
- Volunteers
- 113 people
- Sponsor
- GlaxoSmithKline
End-Stage Renal Disease (ESRD)
Intracellular Phosphate Concentration Evolution During Hemodialysis by MR Spectroscopy
End-stage renal disease is associated with hyperphosphatemia due to a decrease of renal phosphate excretion. This hyperphosphatemia is associated with an increase of cardiovascular risk and mortality.
- Trial name
- CIPHEMO (NCT03119818)
- Testing
- Phosphorus (31P) magnetic resonance spectroscopy, Hemodialysis
- Where
- France
- Volunteers
- 11 people
- Sponsor
- Hospices Civils de Lyon